ライフサイエンスコーパス: adenosine

1 e conjugate, installing a label at N6-methyl-adenosine.

2 of immune function through overproduction of adenosine.

3 acellular nucleotides into immunosuppressive adenosine.

4 ystem either directly or after hydrolysis to adenosine.

5 w high-affinity aptamers that solely bind to adenosine.

6 binds indiscriminately to ATP, ADP, AMP, and adenosine.

7 detect simultaneous events with dopamine and adenosine.

8 ptible to receiving suppressive signals from adenosine.

9 IM cutoff score was optimized to distinguish adenosine.

10 he specific interactions are formed with the adenosine.

11 shown that cells in steeper nonhydrolyzable adenosine- 3', 5'- cyclic monophosphorothioate, Sp- isom

12 Based on the binding mode of adenosine 5'-(alpha,beta-methylene)diphosphate (AOPCP) w

13 adenosine or a non-hydrolyzable ATP analog, adenosine 5'-(gamma-thio)-triphosphate (ATPgammaS) added

14 were caused by the release of extracellular adenosine 5'-diphosphate (ADP) that activated P2Y1 purin

15 d "old/weak." The "young/strong" state 1 has adenosine 5'-diphosphate (ADP)-P (i) bound to Arp2/3 com

16 structure of the enzyme's natural substrate, adenosine 5'-monophosphate (AMP).

17 ceptor P2RX7 and lead to reduced activity of adenosine 5'-monophosphate-activated protein kinase (AMP

18 which catalyzes the conversion of sulfate to adenosine 5'-phosphosulfate (APS), plays a significant r

19 The active sites of RFC are fully bound to adenosine 5'-triphosphate (ATP) analogs, which is expect

20 No major changes in membrane potential or adenosine 5'-triphosphate (ATP) concentration result fro

21 w that CtIP also dramatically stimulates the adenosine 5'-triphosphate (ATP) hydrolysis-driven motor

22 forward to backward steps and the number of adenosine 5'-triphosphate (ATP) molecules hydrolyzed per

23 R activation with 2'(3')-O-(4-Benzoylbenzoyl)adenosine 5'-triphosphate (BzATP).

24 e generation of the primary energy currency, adenosine 5'-triphosphate and its use in the synthesis o

25 t regulate mitochondrial membrane potential, adenosine 5'-triphosphate contents, and reactive oxygen

26 tual screening, we identified P (1),P (5)-di(adenosine-5')-pentaphosphate (Ap5A) ammonium salt as an

27 e diatom, Skeletonema costatum, in utilizing adenosine-5'-triphosphate (ATP) based on incubation expe

28 ke the bacterial flagellar motor (BFM), ATP (adenosine-5'-triphosphate) hydrolysis probably drives bo

29 ns of the direct pathway, dopamine D(1)- and adenosine A(1)-receptors are coexpressed and are mutuall

30 An association between a polymorphism of the adenosine A(2A) receptor (A(2A)R) encoding gene-ADORA2A,

31 in the serial femtosecond crystallography of Adenosine A(2A) receptor (A(2A)R).

32 protein-coupled receptors (GPCR), the human adenosine A(2A) receptor (hA(2A)AR) remains an attractiv

33 f adenosine or alterations in the density of adenosine A(2A) receptors (A(2A)Rs) or their degree of f

34 The adenosine A(3) receptor (A(3)R) belongs to a family of f

35 d signaling evoked by muscarinic (M(2)R) and adenosine (A(1)R) receptor activation in the mouse sinoa

36 Adenosine (A) to inosine (I) RNA editing contributes to

37 oducts, N6-hydroxymethyladenosine (hm6A) and adenosine (A), respectively.

38 ydrolysis of AMP at the cell surface to form adenosine, a potent suppressor of the immune response.

39 boronate molecules is designed to sequester adenosine, a small molecule ubiquitously present in the

40 duced long-term depression (LTD) mediated by adenosine A1 receptor (A1R) activation at corticostriata

41 -induced mechanical allodynia via peripheral adenosine A1 receptor activation.

42 Hypoxia/HIF-1alpha- and extracellular adenosine/A2 adenosine receptor-mediated immunosuppressi

43 racellular adenosine resulting in diminished adenosine A2A receptor (A2AR) stimulation and altered ch

44 aling downstream of CD39 using the selective adenosine A2a receptor antagonist istradefylline.

45 Adenosine, acting at its A2A receptor (A2AR), is a criti

46 Adenosine (Ade) has been identified to stimulate bone fo

47 f regulating production of immunosuppressive adenosine (ADO) through the hydrolysis of AMP.

48 denosine monophosphate (AMP) and 2) AMP into adenosine (Ado) via two representative nucleotidases, CD

49 Extracellular adenosine (ADO), present in high concentrations in the t

50 ise, and pharmacological vasodilatation with adenosine and acetylcholine.

51 Extracellular purines, adenosine and ATP, protected against ALI induced by puri

52 particular attention to N (6)-methylation of adenosine and attempt to place the knowledge gained from

53 rms stacking interactions with the substrate adenosine and basic residues in alpha5 and the alpha5-al

54 In bacterial genomes, methylation occurs on adenosine and cytidine residues to include N6-methyladen

55 d basal type harbored a similar signature of adenosine and ECM profiles; high expression of A(2B) ade

56 ages a purine nucleotide cycle (PNC) between adenosine and inosine monophosphate and adenylosuccinate

57 MS, which include small metabolites such as adenosine and N-acetylaspartate previously associated wi

58 eens against crystal structures of the A(2A) adenosine and the D(4) dopamine receptors were carried o

59 he ensuing microglia-dependent production of adenosine, and the adenosine-mediated suppression of neu

60 investigation into the potential utility of adenosine- and glutamate-signaling as novel therapeutic

61 ATP and its ultimate degradation product adenosine are potent extracellular signalling molecules

62 in the conversion of ATP to immunomodulatory adenosine, are entering clinical trials.

63 flammatory ATP to generate immunosuppressive adenosine, are therefore pivotal in acute inflammation.

64 , offering a versatile solution to utilizing adenosine as a potential therapeutic for tissue repair.

65 Adenosine-based nucleotides, including adenosine tri-, d

66 y not only on preventing the accumulation of adenosine but also on the stabilization of pro-inflammat

67 me CD39 into AMP; AMP is then converted into adenosine by CD73, which is expressed on microglia as we

68 acellular medium, which can be hydrolyzed to adenosine by ectonucleotidases such as ectonucleoside tr

69 nucleoside with potential opposing effects; adenosine can either protect against acute lung injury v

70 Variable doses of adenosine combined with dobutamine were administered to

71 nosine uptake, could raise the extracellular adenosine concentration and dampen chronic inflammation

72 The adenosine content within the patch recedes to the physio

73 okines, and increase their responsiveness to adenosine, could be useful to suppress allergic response

74 identifying spontaneous adenosine events, as adenosine cyclic voltammograms have a primary oxidation

75 undamental RNA modification, is regulated by adenosine deaminase (AD) domain containing proteins.

76 cy caused by gammac-deficiency (SCID X1) and adenosine deaminase (ADA) deficiency.

77 iscovery of a selective covalent modifier of adenosine deaminase (ADA).

78 t ADR-1, a deaminase-deficient member of the adenosine deaminase acting on RNA (ADAR) family, is comp

79 Here, we report that adenosine deaminase acting on RNA (ADAR1), responsible f

80 multiple MS2 binding sites that recruit the adenosine deaminase ADAR2 fused to an MS2 capsid protein

81 In this work, we show that ADAR2 (adenosine deaminase that acts on RNA), an RNA editing en

82 we further evolve ABE7.10 using a library of adenosine deaminase variants to create ABE8s.

83 its prokaryotic orthologs additionally have adenosine deaminase, purine nucleoside phosphorylase, an

84 We propose that MTH1 acts in concert with adenosine deaminase-like protein isoform 1 (ADAL1) to pr

85 Interestingly, down-regulation of adenosine deaminase-related growth factor A (Adgf-A) fro

86 raded in the extracellular space by secreted adenosine deaminase.

87 genous viral elements are silenced by ADARs [adenosine deaminases acting on double-stranded RNA (dsRN

88 Adenosine deaminases acting on RNA (ADARs) convert adeno

89 Adenosine deaminases acting on RNA (ADARs) convert adeno

90 Adenosine Deaminases that act on RNA (ADARs) are enzymes

91 We demonstrate that Adar adenosine deamination activity is necessary for normal l

92 ) is exclusively mobilized by nicotinic acid adenosine dinucleotide-phosphate (NAADP): both Ca(2+) mo

93 effect of adenosine monophosphate (AMP) and adenosine diphosphate (ADP) on flagellar beating is not

94 Structures in the presence or absence of adenosine diphosphate (ADP) suggest that motions of the

95 tructural ensembles for p47-p97 complexes in adenosine diphosphate (ADP)- and adenosine triphosphate

96 els of platelet reactivity were similar with adenosine diphosphate and thrombin.

97 hine blunts the antiplatelet effects of oral adenosine diphosphate receptor blockers.

98 is a calcium-permeable channel activated by adenosine diphosphate ribose metabolites and oxidative s

99 Methods: We used a radiolabled poly(adenosine diphosphate ribose) polymerase (PARP) inhibito

100 wn or putative radiosensitizers such as poly(adenosine diphosphate ribose) polymerase and mammalian-t

101 ed by a rotary ATP synthase to phosphorylate adenosine diphosphate to ATP.

102 owing stimuli to arachidonic acid, collagen, adenosine diphosphate, and thrombin as secondary endpoin

103 repair, are associated with response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibiti

104 of PARPi-FL, a fluorescent inhibitor of poly[adenosine diphosphate-ribose]polymerase 1 (PARP1), which

105 to rifampin, and harbored arr-3, a rifampin adenosine diphosphate-ribosyl transferase.

106 ompared with the wild-type immunotoxin in an adenosine diphosphate-ribosylation assay.

107 tance aggregometry in response to 20 mumol/L adenosine diphosphate.

108 eNAD is degraded to eADP-ribose, eAMP and e-adenosine (eADO) by CD38, ENPP1 and NT5E, (2) with SMCs

109 metabolites eADP-ribose (eADPR), eAMP and e-adenosine (eADO) from tissues and sorted SIP cells using

110 Importantly, CURE does not deaminate adenosine, enabling the high-specificity versions of CUR

111 up of N6-methyl deoxyadenosine and N6-methyl adenosine, epigenetic modifications of emerging importan

112 The SSIM algorithm detected more adenosine events than a previous algorithm based on curr

113 ially, we focused on identifying spontaneous adenosine events, as adenosine cyclic voltammograms have

114 cated (N)-methanocarba (bicyclo[3.1.0]hexyl) adenosines favored high A(3) adenosine receptor (AR) aff

115 verages the transient surge of extracellular adenosine following injury to prolong local adenosine si

116 Because astrocyte-derived adenosine has been shown to regulate synaptic transmissi

117 According to the adenosine hypothesis of schizophrenia, the classically a

118 roup at the C2 position of N(6)-(isopentenyl)adenosine (i(6)A) in the final step of the biosynthesis

119 r, which achieved a detection limit of 1 muM adenosine in 50% serum.

120 e predominant activity for the generation of adenosine in human blood, our results demonstrate a link

121 ino acids in JIP60 activity is to depurinate adenosine in ribosomes.

122 nts due to deficient RNA editing at a single adenosine in their 3'-UTR.

123 Moreover, elevated cochlear adenosine in untreated mice was associated with enhanced

124 o-inosine activity and can specifically edit adenosines in a known substrate.

125 We found that CDNs containing adenosine induced a robust CFTR-mediated chloride secret

126 art coverage within the standard duration of adenosine infusion, and increased the magnitude and reli

127 report that FAMIN phosphorolytically cleaves adenosine into adenine and ribose-1-phosphate.

128 Adenosine is a signaling nucleoside with potential oppos

129 As in other eukaryotes, N (6)-methylation of adenosine is the most abundant and best studied mRNA mod

130 demonstrated that ENT blockade elevated lung adenosine levels and significantly attenuated P. aerugin

131 reactive oxygen species (ROS), and increased adenosine levels characterize tumor microenvironment.

132 We also investigated the changes in adenosine levels in plasma during withdrawal as a surrog

133 ow the enzymatic regulation of extracellular adenosine levels under tissue-damage conditions facilita

134 a pharmacologic approach to reduce placental adenosine levels, we found that enhanced adenosine under

135 The biomaterial-assisted sequestration of adenosine leverages the transient surge of extracellular

136 mRNA methylation at the N6-position of adenosine (m(6)A) enables multiple layers of post-transc

137 N(6) -methylation of adenosine (m(6)A) in RNA regulates many pathophysiologic

138 flow measurement during rest, exercise, and adenosine-mediated hyperemia and were classified as the

139 a-dependent production of adenosine, and the adenosine-mediated suppression of neuronal responses via

140 ced DMS neuronal activities are regulated by adenosine metabolism, receptor signaling, and transport.

141 abidopsis thaliana, the METTL3 homolog, mRNA adenosine methylase (MTA) introduces N (6)-methyladenosi

142 charged homopeptides with 1-100 residues and adenosine mono-, di-, and triphosphate nucleotides are u

143 2'3'-cyclic guanosine monophosphate-adenosine monophosphate (2'3'-cGAMP) is the endogenous l

144 onse is cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) (cGAMP) synthase (cGAS), w

145 adenosine triphosphate (ATP) hydrolysis into adenosine monophosphate (AMP) and 2) AMP into adenosine

146 The modulatory effect of adenosine monophosphate (AMP) and adenosine diphosphate

147 w that while Gh can form hydrogen bonds with adenosine monophosphate (AMP) during incorporation, this

148 Cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) synthase (cGAS) recognizes

149 The activity of the energy sensor adenosine monophosphate (AMP)-activated protein kinase (

150 reduction in plasma adenosine (P = 0.03) and adenosine monophosphate (AMP; P < 0.0001) concentrations

151 the STING agonist bis-(3'-5')-cyclic dimeric adenosine monophosphate (c-di-AMP).

152 hibitory protein Galpha(o1) to reduce cyclic adenosine monophosphate (cAMP) levels in mice and in GPR

153 he GNAS gene, which encodes the 3',5'-cyclic adenosine monophosphate (cAMP) pathway-associated G-prot

154 alone can swiftly increase the 3',5'-cyclic adenosine monophosphate (cAMP) production.

155 o have taken effect through increased cyclic adenosine monophosphate (cAMP) response element binding

156 FTO augmented second messenger 3', 5'-cyclic adenosine monophosphate (cAMP) signaling and suppressed

157 In beta cells, Ca(2+), cyclic adenosine monophosphate (cAMP), and Protein Kinase A (PK

158 e regulatory subunit (PRKAR1A) of the cyclic adenosine monophosphate (cAMP)-dependent protein kinase

159 converging on a ubiquitous messenger, cyclic adenosine monophosphate (cAMP).

160 s as a direct cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic that induces the

161 ne stimulates cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) production in vitro more

162 ulating 2',3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), an agonist of the inter

163 nists further confirmed by functional cyclic adenosine monophosphate experiments.

164 logous protein, and activation of the cyclic adenosine monophosphate response element-binding protein

165 on of nuclear cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) and enhanced int

166 phosphate, deoxyadenosine monophosphate, and adenosine monophosphate), results in ring opening to lin

167 ability of RvD5n-3 DPA to upregulate cyclic adenosine monophosphate, phagocytosis of bacteria, and e

168 Exercise activates adenosine monophosphate-activated kinase (AMPK) and miti

169 The activation of adenosine monophosphate-activated protein kinase (AMPK)

170 Adenosine monophosphate-activated protein kinase (AMPK)

171 f heme oxygenase-1 (HO-1) and phosphorylated adenosine monophosphate-activated protein kinase (pAMPK)

172 LPI induced adenosine monophosphate-activated protein kinase activat

173 It is highly debated how cyclic adenosine monophosphate-dependent regulation (CDR) of th

174 easing the pathway flux, and influencing the adenosine monophosphate/guanosine monophosphate ratio.

175 The cyclic AMP (adenosine monophosphate; cAMP)-hydrolyzing protein PDE4B

176 RNA nucleotide 2-methythio-N(6)-(isopentenyl)adenosine (ms(2)i(6)A).

177 upled to a 6-fold increase in phosphorylated adenosine nucleotide abundance.

178 g of small (2 ul) volumes of a library of 80 adenosine nucleotide analogues is rapid and straightforw

179 g breast cancer cells and, via hemichannels, adenosine nucleotide/nucleoside release into the extrace

180 anges in the intracellular concentrations of adenosine nucleotides are integral to this regulation, w

181 The effect of eATP degradation to adenosine on CXCL8 levels was investigated using agonist

182 coli intratracheally (i.t.) with or without adenosine or a non-hydrolyzable ATP analog, adenosine 5'

183 injection of liposomal suspensions of either adenosine or a selective A2AR agonist, CGS21680, signifi

184 o a reduction of the extracellular levels of adenosine or alterations in the density of adenosine A(2

185 Lastly, lung-targeting gene delivery of adenosine or ATPgammaS downstream effector, myosin phosp

186 Accordingly, treatment with adenosine or ATPgammaS increased oxygen saturation and r

187 ollectively, our study has demonstrated that adenosine or ATPgammaS mitigates E. coli-induced ALI in

188 along with a significant reduction in plasma adenosine (P = 0.03) and adenosine monophosphate (AMP; P

189 ATP-activated P2X7 (P2RX7) and adenosine (P1R) receptors are involved in the progressio

190 The ATP-adenosine pathway functions as a key modulator of innate

191 afficking regulator GNOM and its suppressor, ADENOSINE PHOSPHATE RIBOSYLATION FACTOR GTPase ACTIVATIO

192 Furthermore, adenosine prevented weight loss, tachycardia, and compro

193 Extracellular adenosine, produced through the activity of ecto-5'-nucl

194 Blocking adenosine production by inhibiting nucleotide-metabolizi

195 usually high concentrations of extracellular adenosine promote tumor proliferation through various im

196 alculations led to unambiguous assignment of adenosine radicals as N-7 hydrogen atom adducts.

197 Adenosine radicals tagged with a fixed-charge group were

198 vity in the Drosophila midgut, we identified adenosine receptor (AdoR) as a top candidate gene requir

199 lo[3.1.0]hexyl) adenosines favored high A(3) adenosine receptor (AR) affinity/selectivity, e.g., C2-p

200 receptor (A(3)R) belongs to a family of four adenosine receptor (AR) subtypes which all play distinct

201 ng mode of an antagonist series to the A(2A) adenosine receptor (AR).

202 tive migration through the engagement of the adenosine receptor 1 (ADORA1) and AKT signaling.

203 were treated with trolox, nifedipine, or the adenosine receptor 2A antagonist KW6002.

204 ed suppression of neuronal responses via the adenosine receptor A(1)R are essential for the regulatio

205 Correspondingly, adenosine receptor agonist treatment also limited HDM-dr

206 Additionally, an adenosine receptor agonist was tested to study the mecha

207 Levels of CD39, CD73, and adenosine receptor mRNA were differentially modulated by

208 at the hA(2A)AR, selectivity over all other adenosine receptor subtypes and allowed clear visualizat

209 a/HIF-1alpha- and extracellular adenosine/A2 adenosine receptor-mediated immunosuppression protects t

210 The inhibition of CD73 or the inhibition of adenosine receptors abrogated the ATP effect on CXCL8 se

211 f acute hypoxia with progressive blockade of adenosine receptors and nitric oxide synthase, and by mo

212 e and ECM profiles; high expression of A(2B) adenosine receptors correlated with decreased expression

213 either protect against acute lung injury via adenosine receptors or cause lung injury via adenosine r

214 adenosine receptors or cause lung injury via adenosine receptors or equilibrative nucleoside transpor

215 Adenosine receptors participate in many physiological fu

216 The levels of mRNA expression of adenosine receptors, CD39 and CD73 of periodontitis samp

217 ns are complementarily studied as ligands of adenosine receptors, performing radioligand binding assa

218 asts, an effect regulated by A(2A) and A(2B) adenosine receptors.

219 investigated using agonist and antagonist of adenosine receptors.

220 n (IFN)-gamma, lipopolysaccharide (LPS), and adenosine receptors.

221 xide production, as well as the promotion of adenosine release and expression of certain long non-cod

222 e increases astrocyte Ca(2+), stimulates ATP/adenosine release, and depresses excitatory synaptic tra

223 oduction of ATP and diminished extracellular adenosine resulting in diminished adenosine A2A receptor

224 g injury establishes an in situ stockpile of adenosine, resulting in accelerated healing by promoting

225 or immune cells in hypoxic and extracellular adenosine-rich tumors that are the most resistant to cur

226 t evidence indicates that elevated placental adenosine signaling contributes to preeclampsia (PE).

227 the cAMP/PKA/p-CREB pathway, or by blocking adenosine signaling downstream of CD39 using the selecti

228 basis for the chronically enhanced placental adenosine signaling in PE remains unclear.

229 CD73 and ADORA2B expression and (b) enhanced adenosine signaling through upregulated ADORA2B induces

230 is crucial for the enhancement of placental adenosine signaling.

231 adenosine following injury to prolong local adenosine signaling.

232 may be because of alterations in homeostatic adenosine signaling.SIGNIFICANCE STATEMENT Sleeping sick

233 alterations in extracellular nucleotide and adenosine signalling determine outcomes of inflammation

234 Consistent with these findings, adenosine significantly downregulated TGFbeta signaling

235 o prove it is a broad strategy useful beyond adenosine, SSIM analysis was optimized for dopamine dete

236 T that can be completed within the period of adenosine stress (<=4 minutes) was developed by using co

237 rfusion [ml/min/g] maps were acquired during adenosine stress and at rest following an intravenous co

238 In this retrospective study, consecutive adenosine stress and rest perfusion scans were acquired

239 Resting and adenosine stress myocardial blood flow (MBF) and myocard

240 ging, while evidence of the benefits of both adenosine stress perfusion cardiac MRI and coronary CT a

241 In healthy dogs, T2 MRI at adenosine stress was greater than at rest (mean rest vs

242 tive T1 maps were acquired before and during adenosine stress, and after contrast (0.2 mmol/kg) at re

243 er contrast (0.2 mmol/kg) at rest and during adenosine stress, rendering rest and stress ECV maps.

244 After a 30-minute waiting period, adenosine testing (30 mg) was used to reveal dormant PV

245 In addition to sequestering endogenous adenosine, the biomaterial is also able to deliver exoge

246 Extracellular adenosine, the ligand for AdoR, is a small metabolite th

247 selection of the precursor mRNA branch-site adenosine, the nucleophile for the first step of splicin

248 -1alpha-driven accumulation of extracellular adenosine to (a) unleash antitumor immune cells from inh

249 m enterocytes is necessary for extracellular adenosine to activate AdoR and induce ISC overproliferat

250 2/3 enzyme and we confirm the deamination of adenosine to inosine and the formation of tRNAValIACin v

251 act on RNA (ADARs) are enzymes that catalyze adenosine to inosine conversion in dsRNA, a common form

252 ine deaminases acting on RNA (ADARs) convert adenosine to inosine in double-stranded RNA.

253 iomaterial is also able to deliver exogenous adenosine to the site of injury, offering a versatile so

254 ine deaminases acting on RNA (ADARs) convert adenosines to inosines in double-stranded RNA (dsRNA) in

255 finity dsRNA-binding proteins that deaminate adenosines to inosines in pre-mRNA hairpins and also exe

256 Furthermore, purified axoplasm exhibits adenosine-to-inosine activity and can specifically edit

257 We find widespread loss of adenosine-to-inosine editing of Alu RNAs in MS.

258 inase acting on RNA (ADAR1), responsible for adenosine-to-inosine editing of RNA, is required for reg

259 Adenosine-to-inosine RNA editing, a fundamental RNA modi

260 Adenosine-based nucleotides, including adenosine tri-, di-, and mono-phosphate, are controlled

261 As a ring-shaped adenosine triphosphatase (ATPase) machine, cohesin organ

262 lation of the Na(+)/K(+) exchanger ATPalpha (adenosine triphosphatase alpha) in glia may be modulated

263 Here, using helicase and adenosine triphosphatase assays we show that a complex c

264 t the a3-subunit of the vacuolar-type (H(+))-adenosine triphosphatase is required for establishing a

265 Vesicular- or vacuolar-type adenosine triphosphatases (V-ATPases) are ATP-driven pro

266 t transporter from Aquifex aeolicus bound to adenosine triphosphate (ATP) and in a lipid environment,

267 Measurements of adenosine triphosphate (ATP) and metabarcoding of enviro

268 vity" and "alkyl-induced" pockets within the adenosine triphosphate (ATP) binding site of PI3Kgamma.

269 CofB also shows activation by adenosine triphosphate (ATP) despite the reaction requir

270 tween the genomes is essential for efficient adenosine triphosphate (ATP) generation.

271 action-diffusion numerical simulations of 1) adenosine triphosphate (ATP) hydrolysis into adenosine m

272 DEAH helicases couple adenosine triphosphate (ATP) hydrolysis to conformationa

273 ensely packed adjacent to myofibrils because adenosine triphosphate (ATP) is needed to fuel sarcomere

274 In tissue infections, adenosine triphosphate (ATP) is released into extracellu

275 bnormal mitochondrial fragmentation, reduced adenosine triphosphate (ATP) levels and a higher fatigab

276 a wide range of cellular functions including adenosine triphosphate (ATP) production, lipid synthesis

277 The adenosine triphosphate (ATP) synthase in human mitochond

278 tion, stressed or infected cells can release adenosine triphosphate (ATP) to the extracellular medium

279 ciated with P(i) liberation in real-time for adenosine triphosphate (ATP) turnover by myosin, the act

280 d cycle (TCA) intermediates and synthesis of adenosine triphosphate (ATP), but the reason for glutama

281 omplexes in adenosine diphosphate (ADP)- and adenosine triphosphate (ATP)-bound conformations, highli

282 gase (NgrRnl) exemplifies the Rnl5 family of adenosine triphosphate (ATP)-dependent polynucleotide li

283 First, we build an adenosine triphosphate (ATP)-driven DNA nanogatekeeper.

284 ngage specific protein substrates before the adenosine triphosphate (ATP)-fueled mechanical unfolding

285 with increased intracellular charge, higher adenosine triphosphate level, quicker substrate consumpt

286 Increased intracellular adenosine triphosphate levels activate the purinergic re

287 etion of cellular guanosine triphosphate and adenosine triphosphate pools, and is counteracted by its

288 enes in HFpEF were enriched in mitochondrial adenosine triphosphate synthesis/electron transport, pat

289 ATPase (enzymatic hydrolysis of adenosine triphosphate to inorganic phosphate) levels we

290 their central role in energetics, producing adenosine triphosphate to power most cellular processes.

291 mononucleotide) and tissues (eg, succinate, adenosine triphosphate, hypoxia-inducible factor-1alpha,

292 e we show that liposomes containing calcium, adenosine triphosphate, or carboxyfluorescein are tether

293 Multidrug resistance-associated protein 1 (adenosine triphosphate-binding cassette subfamily C memb

294 ognition of a replication error it undergoes adenosine triphosphate-dependent conformational changes

295 ranes, and energy transfer molecules such as adenosine triphosphate.

296 tal adenosine levels, we found that enhanced adenosine underlies increased placental HIF-1alpha in an

297 d that dipyridamole, which inhibits cellular adenosine uptake, could raise the extracellular adenosin

298 de transporter (ENT)-dependent intracellular adenosine uptake.

299 a during withdrawal as a surrogate for brain adenosine, which plays a role in fine-tuning synaptic gl

300 inhibitor C10-AMS [5'-O-(N-decanylsulfamoyl)adenosine], which mimics the tightly bound acyl-AMP reac